JOHNSON & JOHNSON (JNJ.DE) Fundamental Analysis & Valuation

FRA:JNJ • US4781601046

Current stock price

204.55 EUR
-0.95 (-0.46%)
Last:

This JNJ.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. JNJ.DE Profitability Analysis

1.1 Basic Checks

  • In the past year JNJ was profitable.
  • JNJ had a positive operating cash flow in the past year.
  • Each year in the past 5 years JNJ has been profitable.
  • JNJ had a positive operating cash flow in each of the past 5 years.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • With an excellent Return On Assets value of 13.46%, JNJ belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
  • With a decent Return On Equity value of 32.87%, JNJ is doing good in the industry, outperforming 78.43% of the companies in the same industry.
  • JNJ has a Return On Invested Capital of 14.37%. This is in the better half of the industry: JNJ outperforms 72.55% of its industry peers.
  • JNJ had an Average Return On Invested Capital over the past 3 years of 16.34%. This is in line with the industry average of 17.40%.
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROIC 14.37%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • With an excellent Profit Margin value of 28.46%, JNJ belongs to the best of the industry, outperforming 92.16% of the companies in the same industry.
  • JNJ's Profit Margin has improved in the last couple of years.
  • JNJ has a better Operating Margin (27.78%) than 72.55% of its industry peers.
  • JNJ's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 67.92%, JNJ is in line with its industry, outperforming 49.02% of the companies in the same industry.
  • In the last couple of years the Gross Margin of JNJ has remained more or less at the same level.
Industry RankSector Rank
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

5

2. JNJ.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), JNJ is creating some value.
  • Compared to 1 year ago, JNJ has about the same amount of shares outstanding.
  • The number of shares outstanding for JNJ has been reduced compared to 5 years ago.
  • The debt/assets ratio for JNJ is higher compared to a year ago.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 5.02 indicates that JNJ is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of JNJ (5.02) is better than 72.55% of its industry peers.
  • JNJ has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as JNJ would need 2.43 years to pay back of all of its debts.
  • JNJ has a Debt to FCF ratio of 2.43. This is in the better half of the industry: JNJ outperforms 74.51% of its industry peers.
  • A Debt/Equity ratio of 0.56 indicates that JNJ is somewhat dependend on debt financing.
  • JNJ has a Debt to Equity ratio of 0.56. This is comparable to the rest of the industry: JNJ outperforms 54.90% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for JNJ, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Altman-Z 5.02
ROIC/WACC1.53
WACC9.41%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.3 Liquidity

  • A Current Ratio of 1.03 indicates that JNJ should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.03, JNJ is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
  • JNJ has a Quick Ratio of 1.03. This is a bad value and indicates that JNJ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of JNJ (0.77) is worse than 72.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.77
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

5

3. JNJ.DE Growth Analysis

3.1 Past

  • JNJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.11%, which is quite good.
  • Measured over the past 5 years, JNJ shows a small growth in Earnings Per Share. The EPS has been growing by 6.11% on average per year.
  • JNJ shows a small growth in Revenue. In the last year, the Revenue has grown by 6.05%.
  • JNJ shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.67% yearly.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.75% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 6.02% on average over the next years.
EPS Next Y7.85%
EPS Next 2Y8.27%
EPS Next 3Y8.5%
EPS Next 5Y8.75%
Revenue Next Year7.24%
Revenue Next 2Y6.55%
Revenue Next 3Y6.35%
Revenue Next 5Y6.02%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

2

4. JNJ.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 21.90, the valuation of JNJ can be described as rather expensive.
  • The rest of the industry has a similar Price/Earnings ratio as JNJ.
  • JNJ's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.91.
  • With a Price/Forward Earnings ratio of 20.30, JNJ is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JNJ is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of JNJ to the average of the S&P500 Index (23.69), we can say JNJ is valued inline with the index average.
Industry RankSector Rank
PE 21.9
Fwd PE 20.3
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • JNJ's Enterprise Value to EBITDA ratio is in line with the industry average.
  • JNJ's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 28.91
EV/EBITDA 17.3
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates JNJ does not grow enough to justify the current Price/Earnings ratio.
  • JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.79
PEG (5Y)3.59
EPS Next 2Y8.27%
EPS Next 3Y8.5%

5

5. JNJ.DE Dividend Analysis

5.1 Amount

  • JNJ has a Yearly Dividend Yield of 2.16%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.94, JNJ pays a bit more dividend than its industry peers.
  • JNJ's Dividend Yield is comparable with the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 2.16%

5.2 History

  • The dividend of JNJ is nicely growing with an annual growth rate of 7.68%!
Dividend Growth(5Y)7.68%
Div Incr Years7
Div Non Decr Years7
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 46.19% of the earnings are spent on dividend by JNJ. This is a bit on the high side, but may be sustainable.
  • The dividend of JNJ is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP46.19%
EPS Next 2Y8.27%
EPS Next 3Y8.5%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

JNJ.DE Fundamentals: All Metrics, Ratios and Statistics

JOHNSON & JOHNSON

FRA:JNJ (4/8/2026, 7:00:00 PM)

204.55

-0.95 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.62%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap492.68B
Revenue(TTM)94.19B
Net Income(TTM)26.80B
Analysts76.25
Price Target200.81 (-1.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.16%
Yearly Dividend4.46
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years7
Div Non Decr Years7
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)0%
PT rev (3m)9.22%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)-3.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)1.83%
Valuation
Industry RankSector Rank
PE 21.9
Fwd PE 20.3
P/S 6.04
P/FCF 28.91
P/OCF 23.21
P/B 6.98
P/tB N/A
EV/EBITDA 17.3
EPS(TTM)9.34
EY4.57%
EPS(NY)10.08
Fwd EY4.93%
FCF(TTM)7.08
FCFY3.46%
OCF(TTM)8.81
OCFY4.31%
SpS33.84
BVpS29.29
TBVpS-6.33
PEG (NY)2.79
PEG (5Y)3.59
Graham Number78.46
Profitability
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROCE 18.03%
ROIC 14.37%
ROICexc 16.57%
ROICexgc 67.45%
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
FCFM 20.91%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
ROICexc(3y)19.6%
ROICexc(5y)18.23%
ROICexgc(3y)74.51%
ROICexgc(5y)73.44%
ROCE(3y)20.24%
ROCE(5y)18.7%
ROICexgc growth 3Y3.9%
ROICexgc growth 5Y-2.01%
ROICexc growth 3Y8.52%
ROICexc growth 5Y5.62%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Debt/EBITDA 1.36
Cap/Depr 64.4%
Cap/Sales 5.13%
Interest Coverage 6.81
Cash Conversion 72.86%
Profit Quality 73.49%
Current Ratio 1.03
Quick Ratio 0.77
Altman-Z 5.02
F-Score4
WACC9.41%
ROIC/WACC1.53
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.85%
EPS Next 2Y8.27%
EPS Next 3Y8.5%
EPS Next 5Y8.75%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year7.24%
Revenue Next 2Y6.55%
Revenue Next 3Y6.35%
Revenue Next 5Y6.02%
EBIT growth 1Y12.82%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.18%
EBIT Next 3Y11.51%
EBIT Next 5Y8.55%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%

JOHNSON & JOHNSON / JNJ.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE.


What is the valuation status of JOHNSON & JOHNSON (JNJ.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


How profitable is JOHNSON & JOHNSON (JNJ.DE) stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 7 / 10.


What is the financial health of JOHNSON & JOHNSON (JNJ.DE) stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10.


Can you provide the expected EPS growth for JNJ stock?

The Earnings per Share (EPS) of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 7.85% in the next year.